Many individuals are reluctant to receive the Shingrix vaccine, but the potential consequences of shingles can be debilitating. An example is a reported case where an elderly man suffered severely after contracting shingles. Despite having received an older vaccine, he experienced intense pain that led to multiple hospitalizations.
The man now battles post-herpetic neuralgia (PHN), a condition that causes chronic pain following shingles. Despite treatment options like morphine and gabapentin, his daily pain remains nearly intolerable, impacting his quality of life significantly. He has transitioned from an active lifestyle—once engaging in bowling and volunteering—to being largely housebound, indicative of the severe effects of this condition.
Understanding Shingrix and Its Benefits
The previous shingles vaccine, Zostavax, has been succeeded by Shingrix, which demonstrates superior effectiveness. Recent studies highlight not only its role in preventing shingles but also its additional benefits for older adults.
Research Findings on Shingrix
A significant study presented at IDWeek analyzed the health outcomes of over 174,000 older Americans across more than 100 health care systems. The research focused on individuals who received the Shingrix vaccine compared to those who opted for pneumonia vaccination.
- 50% reduction in the likelihood of developing vascular dementia
- 27% lower chance of experiencing dangerous blood clots
- 25% decreased risk for heart attacks and strokes
- 21% reduction in overall mortality during the follow-up, which ranged from three months to seven years
These findings underscore the importance of considering the Shingrix vaccine, especially for the elderly. It may offer protection beyond shingles, potentially leading to significant health benefits.
For those weighing the decision on vaccination, the health risks associated with shingles and the potential long-term benefits of Shingrix should be compelling factors to consider.
